National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) for Breast Cancer Indication
- Friday, November 29, 2019, 7:15
- Environment
- Add a comment
SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ — On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company’s lead innovative product Epidaza® (Chidamide), an oral subtype-selective histone deacetylase (HDAC)…
About the Author
adminasapcorp has written 37720 stories on this site.